<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141839</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Epidermic growth factor receptor (EGFR) in glioblastomas: the mechanism of tumorigenesis and its role as a therapeutic target</dc:title>
<dc:description xml:lang="en">A glioblastoma is a primary brain tumour that is very aggressive and resistant to conventional treatment with chemo- or radiotherapy. Given that epidermic growth factor receptor (EGFR) is altered in 50% of glioblastomas, it is currently one of the most promising therapeutic targets in this kind of tumour. Yet, inhibitors of the kinase activity of EGFR have yielded poor results in clinical trials with patients with glioblastomas. In this review we analyse the function of EGFR in glioblastomas and outline the therapeutic approaches aimed against this receptor in this kind of tumour. This sort of analysis could be a starting point for improving the design of future therapies for glioblastomas, based on inhibiting the EGFR function (AU)</dc:description>
<dc:creator>Zahonero, C</dc:creator>
<dc:creator>Sepúleda, J. M</dc:creator>
<dc:creator>Sánchez Gómez, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El glioblastoma es un tumor cerebral primario muy agresivo y resistente al tratamiento convencional con quimio y radioterapia. Dado que el receptor del factor de crecimiento epidérmico (EGFR) se encuentra alterado en el 50% de los glioblastomas, representa actualmente una de las dianas terapéuticas más prometedoras en este tipo de tumores. Sin embargo, los inhibidores de la actividad cinasa del EGFR han generado escasos resultados en ensayos clínicos con pacientes con glioblastoma. En esta revisión se analiza la función del EGFR en el glioblastoma y se describen las aproximaciones terapéuticas dirigidas frente a dicho receptor en este tipo de tumores. Este tipo de análisis podría constituir un punto de partida para mejorar el diseño de futuras terapias para los glioblastomas, basadas en la inhibición de la función del EGFR (AU)</dc:description>
<dc:source>Rev Neurol;61(2): 85-93, 16 jul., 2015. ilus</dc:source>
<dc:identifier>ibc-141839</dc:identifier>
<dc:title xml:lang="es">El receptor del factor de crecimiento epidérmico (EGFR) en el glioblastoma: mecanismo de tumorigénesis y papel como diana terapéutica</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d55206^s22033</dc:subject>
<dc:subject>^d28622^s22074</dc:subject>
<dc:subject>^d37364^s22002</dc:subject>
<dc:subject>^d32227^s22031</dc:subject>
<dc:subject>^d37364^s22000</dc:subject>
<dc:subject>^d37364^s22044</dc:subject>
<dc:subject>^d23484^s22039</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d37364^s22015</dc:subject>
<dc:subject>^d32227^s22033</dc:subject>
<dc:subject>^d23484^s22045</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d9128^s22033</dc:subject>
<dc:subject>^d55206^s22053</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d9128^s22031</dc:subject>
<dc:subject>^d31846^s22012</dc:subject>
<dc:subject>^d28622^s22048</dc:subject>
<dc:subject>^d28622^s22039</dc:subject>
<dc:subject>^d31846^s22044</dc:subject>
<dc:subject>^d31846^s22053</dc:subject>
<dc:subject>^d31846^s22064</dc:subject>
<dc:subject>^d28622^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201507</dc:date>
</metadata>
</record>
</ibecs-document>
